BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19691096)

  • 21. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
    Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
    J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
    Raza A; Reeves JA; Feldman EJ; Dewald GW; Bennett JM; Deeg HJ; Dreisbach L; Schiffer CA; Stone RM; Greenberg PL; Curtin PT; Klimek VM; Shammo JM; Thomas D; Knight RD; Schmidt M; Wride K; Zeldis JB; List AF
    Blood; 2008 Jan; 111(1):86-93. PubMed ID: 17893227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
    Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Matsuda A; Tohyama K; Taniwaki M; Takeshita K; Takatoku M; Ozawa K
    Int J Hematol; 2009 Oct; 90(3):353-360. PubMed ID: 19705057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
    Chan O; Ali NA; Sallman D; Padron E; Lancet J; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e467-e476. PubMed ID: 35101379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
    Giagounidis AA; Germing U; Aul C
    Clin Cancer Res; 2006 Jan; 12(1):5-10. PubMed ID: 16397017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
    Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
    Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
    Komrokji RS; List AF
    Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
    Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
    PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
    Oliva EN; Latagliata R; Laganà C; Breccia M; Galimberti S; Morabito F; Poloni A; Balleari E; Cortelezzi A; Palumbo G; Sanpaolo G; Volpe A; Specchia G; Finelli C; D'Errigo MG; Rodà F; Alati C; Alimena G; Nobile F; Aloe Spiriti MA
    Leuk Lymphoma; 2013 Nov; 54(11):2458-65. PubMed ID: 23432724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetic analysis in patients with myelodysplastic syndrome.
    Hu N; Bian M
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(3):135-9. PubMed ID: 2098765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS; Padron E; Ebert BL; List AF
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
    Giagounidis A; Fenaux P; Mufti GJ; Muus P; Platzbecker U; Sanz G; Cripe L; Von Lilienfeld-Toal M; Wells RA
    Ann Hematol; 2008 May; 87(5):345-52. PubMed ID: 18265982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.
    Sakai H; Miura I; Arai A
    J Clin Exp Hematop; 2022 Sep; 62(3):158-163. PubMed ID: 35732408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.
    Adès L; Boehrer S; Prebet T; Beyne-Rauzy O; Legros L; Ravoet C; Dreyfus F; Stamatoullas A; Chaury MP; Delaunay J; Laurent G; Vey N; Burcheri S; Mbida RM; Hoarau N; Gardin C; Fenaux P
    Blood; 2009 Apr; 113(17):3947-52. PubMed ID: 18987358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
    Olney HJ; Le Beau MM
    Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.